NuVasive Announces Outstanding Showing at NASS 2012

NuVasive Announces Outstanding Showing at NASS 2012 
SAN DIEGO, CA -- (Marketwire) -- 10/29/12 --   NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
featured its procedural solutions and sophistication from years of
experience in lateral approach spine surgery at the North American
Spine Society (NASS) 2012 Annual Meeting. 
The Company showcased a number of innovative products designed to
drive market penetration. The new medialized posterior approach known
as MAS(R) PLIF is designed to minimize muscle disruption associated
with traditional posterior approach with a less invasive exposure for
pathology that requires direct posterior decompression. The
Precept(R) Posterior Fixation System which simplifies procedures by
offering more practical MIS instrumentation for even the most
advanced constructs. Additional new product standouts included new
application specific implants for XLIF(R) to recreate sagittal
alignment, expansions of MAS(R) TLIF, and the new MaXcess-C(TM)
retractor for the cervical spine. As well, surgeon interest in the
power of NuVasive's integrated neuromonitoring solutions was very
high.  
The Company culminated NASS 2012 with the announcement that the U.S.
Food and Drug Administration (FDA) granted Premarket Approval (PMA)
for its PCM(R) Cervical Disc System. The device has many design
features that make it a truly unique product offering compared to
other cervical motion preserving devices currently or imminently on
the market. Its low-profile design enables it to be minimally
disruptive to the adjacent anatomy, which supports it as a viable
treatment option for levels adjacent to prior fusions. Additionally,
the Company showcased the extensive volume of strong clinical data
related to the device. 
Alex Lukianov, Chairman and Chief Executive Officer of NuVasive said,
"Our surgeon booth traffic was clearly the highest and most
consistent versus our competitors. We had surgeon presentations to
emphasize expanded applications for XLIF and the breadth and depth of
the NuVasive product offering, with demonstrations of MAS-TLIF, ILIF,
and MAS-PLIF. Surgeon adoption of those solutions, in addition to the
innovative new solutions launched at NASS, such as th
e PCM Cervical
Disc System and our Precept Posterior Fixation System, will drive
penetration and growth for years to come. I am exceptionally proud of
the team at NuVasive that worked to make NASS 2012 a tremendous
success. I look forward to building on the momentum from the meeting
to affect a solid close to 2012 and a great start to 2013." 
The NuVasive booth also featured the Company's patient and industry
advocacy efforts dedicated to improving patient access to care.
Basketball Hall-of-Famer, Bill Walton emphasized the success of The
Better Way Back program, which was designed to build a community of
support for individuals suffering from chronic back and leg pain.
Another highlight was the Spine Care Alliance, a program for patients
who have exhausted the appellate process for medically indicated
spine surgery, which has been very effective in helping to overturn
fusion denials. 
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $7.9
billion global spine market. 
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines several
categories of solutions that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and safe,
easy repro
ducibility for the surgeon: a proprietary software-driven
nerve avoidance system and intra-operative monitoring support;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 75 products today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
risk that spine surgeons may be slow to adopt our Precept Posterior
Fixation system, our products for MAS PLIF or MAS TLIF, our PCM
Cervical Disc System or our other products; the risk that future
patient studies or clinical experience may indicate that treatment
with the PCM Cervical Disc System or our other products does not
improve patient outcomes; the risk that surgeon interest in our new
products and our integrated neuromonitoring solutions may not result
in commercial success; the risk that products may not perform as
intended and may therefore not achieve commercial success; the risk
that competitors may develop superior products or may have a greater
market position enabling more successful commercialization; the risk
that insurance payers may refuse to reimburse healthcare providers
for the use of NuVasive's products the risk that additional clinical
data may call into question the benefits of NuVasive's products to
patients, hospitals and surgeons; and other risks and uncertainties
more fully described in NuVasive's press releases and periodic
filings with the Securities and Exchange Commission.NuVasive's public
filings with the Securities and Exchange Commission are available at
www.sec.gov. NuVasive assumes no obligation to update any
forward-looking statement to reflect events or circumstances arising
after the date on which it was made. 
Contact:
Michael J. Lambert
EVP & Chief Financial Officer
NuVasive, Inc.
858.909.3394
investorrelations@nuvasive.com 
Investors:
Patrick F. Williams
Vice President, Strategy & Investor Relations
NuVasive, Inc.
858-638-5511
investorrelations@nuvasive.com 
Media:
Nicholas S. Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.